Ekf Diagnostics Share Discussion Threads

[tongosti] 18/2/2022 08:33

Don’t think the period since Nov 2020 (15 months and counting) can be qualified as “current”;. As some you you may remember, I turned skeptic the day the c19 vaccine was announced. That was a very different world to what it is now.

Point it, EKF is not going down because of what’s happening in the wider markets "now". The decline (starting with the refusal, for a long time, to go up on seemingly good updates as we were reminded on this board frequently) has started way before that. This much is fact, and one I was challenging folks to think about when this was at 80+

[wan] 18/2/2022 04:55

Tongosti has been and indeed is 'currently' proving more right than me! However, we both previously agreed that the market didn't like the Trading Update.

I appreciate that markets are volatile as they adjust to interest rates and even the possibility of war etc, but with the market pricing in something very different to what I think regarding EKF (and I could ultimately be wrong), until it becomes clearer about what we don't currently know, there is not very much that's currently worth saying (repeating).

[tongosti] 17/2/2022 11:55

While bizarre broken record ideas help rationalise one falling sleep at the wheel, Mr Market has printed 53. Almost 40% down from its highs but nothing to worry about ain't it. Lol.

[wan] 17/2/2022 07:53

I am sure not many would rely too much, in investment terms, on what the UK government decides, particularly with regard to supporting available solutions within the UK, but it will be interesting to see the outcome from the following, which is important and obviously has ramification over and beyond investing alone -

UK to revamp biosecurity strategy in wake of Covid-19
Virus exposed ‘profound shortcomings’ to approach published in 2018

16th February 2022
The UK is revamping its approach to biosecurity after Covid-19 exposed major shortcomings in its ability to respond to biological threats, including the coronavirus pandemic.

The new approach will update Britain’s last biological security strategy, published in 2018, which warned of the need to “co-ordinate” government actions better and for a “truly comprehensive approach” to meet biological risks, including pandemics.

Microsoft co-founder Bill Gates last year suggested that the US and UK would have to spend “tens of billions” on research and development to guard against a future pandemic and urged the World Health Organization to establish a task force for disease surveillance.

Sarah Gilbert, who led development of the AstraZeneca Covid vaccine, has also urged politicians to invest in prevention.

“This will not be the last time a virus threatens our lives and our livelihoods,” she said in a recent lecture. “We cannot allow a situation where we have gone through . . . and then find that the enormous economic losses we have sustained mean that there is still no funding for pandemic preparedness”.

Under the broad overriding concept of “health resilience”, it will also cover logistical aspects of health, including medical supply chains and border controls.

The updated strategy will be released later this year, after incorporating evidence from health and security experts.

Full story -

EKF are already a supplier to public health systems customers in the UK

[tongosti] 17/2/2022 07:49

Dated indeed pal - the market was voting 85 at its highest last year.

[km18] 16/2/2022 18:22

...a little dated from last year...

EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. Current market cap is around £322m.

The company today issued a trading update for the 6 months ending 30 June 2021. Strong trading from Q1 extended through Q2 and management remain confident that trading for the full year will be in-line with already materially-upgraded management expectations.

Revenues for H1 2021 were £38.56m up 46.4% on H1 2020 (£26.33m) and the Company expects to report adjusted EBITDA in the region of £12.75m up 42.8% on H1 2020  (£8.93m). This is a pretty strong rate of expansion, albeit positively impacted by COVID and ongoing strong demand for contract manufacturing services for COVID-19 sample collection devices and associated kits....from WealthOracleAM

[tongosti] 15/2/2022 14:47

WAN's div yield must be more and more attractive (for him and gm's of the world) by the hour now innit. Lol

[wan] 15/2/2022 10:19

Staying with the UK (which I appreciate is nothing to get too excited about, but it's perhaps one to watch) -

Recently I noticed that a leading company in the supply, logistics and support of point of care medical diagnostic devices and consumables to the UK Healthcare sector, started selling an EKF product, the 'Prospect' Hemo Control -


Today I was catching up with a line of research and I noticed that Prospect Diagnostics appear to have launched/made available an EKF private label product too, otherwise known as EKF's DiaSpect Tm -

[tongosti] 15/2/2022 08:52

55 printing.

That’s some direction of travel innit.

P.S. there is an idiot following me around these boards. he/she changes aliases constantly. recently calling oneself drew - just letting you know folks.

[wan] 15/2/2022 08:30

Direction of travel -

The following article exemplifies the global opportunity in my view, from a molecular testing perspective (albeit I seem to have been waiting a long time for it to come to pass proper in the UK in terms of diagnostics generally!), but as a result of pandemic the dynamics have materially changed, let's see if the UK realises it and acts on the clear benefits of prevention!

How COVID-19 has helped revolutionise UK diagnostics

BY ADRIAN SMITH 14 FEBRUARY 2022

Adrian Smith, general manager, Hologic UK and Ireland, explains how the pandemic has helped the industry act with clarity and determination to revolutionise UK diagnostics.

The COVID-19 pandemic has shown us the importance of building a health service focused on prevention rather than cure and technological advances in the diagnostics sector, including automated on-demand molecular testing, is set to significantly improve the health outcomes of millions of patients.

We know that preventing disease has many benefits over curing it. The UK Government published its vision in 2018 to transform the UK’s approach, stating that around £14 of social benefit comes for every £1 spent across a broad range of areas of prevention. But despite this clear benefit, the government’s own findings showed that we spent 60% of public funding for healthcare on cure and rehabilitation, and only 5% on prevention. That amounted to £97 billion a year on treating diseases, and only £8 billion on preventing them.

So, where should the focus lie when it comes to redesigning a health system that prioritises prevention?

At the heart of earlier detection, diagnosis, and prevention lies diagnostics, also echoed in the government’s Life Science’s Vision. And if you look at the innovation in the molecular diagnostics field, you will see three powerful forces reframing perceptions of what is possible.

Increasing adoption of new molecular diagnostic platforms

Of course, with every new technology, there are challenges to overcome. These new approaches are more expensive and moving away from traditional tried-and-tested approaches always takes time. But the direction of travel is clear. Modern molecular diagnostic platforms are quickly rising to the ascendancy when it comes to identifying infectious and testing diseases.

Full story -

[tongosti] 15/2/2022 08:05

Delusions are a very powerful force in the markets.Charles MacKay's "Extraordinary delusions and the madness of crowds" is a book everyone should read.

[wan] 15/2/2022 07:58

Excellent news today over at Verici, which is a very important step towards product commercialisation.

And confirms that the positive direction of travel, in terms of development and commercialisation, continues, with more to follow before the end of the current quarter ending March 31st (not that I think the trend will stop there!).

I also believe that options abound in terms of an accelerated commercialisation strategy. Today's news will help increase those options!

Option 1 - Verici already has a CLIA waived lab

Option 2 - So do EKF

Option 3 - Many other partnering opportunities!

[sirshagalot] 11/2/2022 11:36

I have turnaround @ 54-55p range i will prob buy into this again.
Tongi,s call was correct and he that bends with the winds survives to invest again.
In my opinion 48p is a little too low for me, but hey thats why you see cars for sale @ £19,999.99 .
"Caveat emptor" and all that jazz.

[tongosti] 11/2/2022 10:41

When I made the original 48p call this was at 71. More than half way there.

[wan] 09/2/2022 09:58

For those interested, this video recorded in October 2021 is the most recent update from Purissima, describing (to a degree) the benefits of their technology that utilises fermentation which is hugely scalable, indicating that their first two products (among many others planned) were imminent -

[tongosti] 09/2/2022 09:15

Amazed a few take this chap's arguments seriously. Live and let live - it takes two to make a market ain't it. PS. His buying the absolute lows in March 2020 is up there - just when one thinks has heard it all!

[tongosti] 09/2/2022 08:54

Phenomenal day in the wider markets. Thought rising tide lifts all boats? It does but only the solid ones apparently. mg - commiserations.

[tongosti] 08/2/2022 11:49

58 printing - Mr Market gave wans of the world enough warnings in advance folks. Hardly a shocker.

[tongosti] 04/2/2022 15:02

1- Markets were disappointed with the latest company report. If that fundamental release didn't do the trick, what will?2- Even in good wider market days, this share goes down - such poor relative strength is very telling and it's one of the very few statistics that has genuine (ex-ante) predicting power in markets3 - The breakdown from a 15 month range, makes very clear the likely path of least resistance 4 - 48 is a key volume nod, historically. More often than not, such volume concentration points acts as magnets to the share price 5 - We hardly see any bear case on this board. If anything, there is one chap who keeps playing the violin on the ship's deck (daily, without ever changing the tune) with no regard to what's going on around him. The crowd is happy to follow. Classic inflection point tell, in my experience.

[jsredbird] 04/2/2022 14:44

Tong, what leads you to believe that target of 48 is in the works?

[wan] 04/2/2022 12:45

In considering healthcare generally (if you get my drift), after recent recruitment efforts, Amazon reported yesterday that they now have 1.6m employees, and that's excluding delivery drivers!

Given Amazons developments in healthcare, that's providing them with a lot of new healthcare customers (and providing healthcare benefits), especially when you add the employee family members in.

[tongosti] 04/2/2022 12:14

Ship heading further South - 48 beckons. Does one sleepwalk into you know what or manage risk? Tough choice ...

[wan] 04/2/2022 08:01

Many more diagnostic players have reported over the last few days.

In terms of COVID testing, The large companies have reported a mixed quarter picture compared to a year ago (when testing was extremely high), but acknowledged that testing demand has since increased due the omicron wave. And although the COVID testing situation is still very dynamic, they are factoring in an increase in testing (biased to the first half of 2022). One early example of the type of increase was from Quest Diagnostics who performed roughly 7.9 million COVID-19 molecular tests during Q4, but reported conducting a similar volume of testing in January 2022 alone. With several companies stating that they expect COVID PCR testing will play an ongoing role in the future, implying $100 million in revenue per quarter when COVID-19 becomes endemic.

Moving on, importantly the large diagnostic companies continue to report that their core businesses are performing very well and are growing, and have thus raised their outlooks for 2022.